Stocks · News reference
Lantern Pharma Announces EMA Clearance Of An Investigator-Initiated Phase 1b/2 Clinical Trial Of LP-184 In Advanced, Recurrent Bladder Cancer
The study will be conducted at Rigshospitalet in Copenhagen — Denmark’s national referral center for urologic cancers — in collaboration with Professor Helle Pappot, MD, DMSc, a leading authority in the treatment of
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
8-K filing — Lantern Pharma Inc. (LTRN)
Filed: 2026-10-01 AccNo: 0001493152-26-045344 Size: 200 KB Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
Lantern Pharma Issued Notice Of Allowance From U.S. Patent And Trademark Office For Application Titled Method For Treating Blood Cancers
Lantern Pharma Inc. (NASDAQ:LTRN), an AI‑driven precision oncology company transforming the cost, pace, and timeline of oncology drug discovery and development, today announced that the United States Patent and
Lantern Pharma Q2 2026 Earnings Call: Complete Transcript
Lantern Pharma (NASDAQ:LTRN) reported second-quarter financial results on Friday. The transcript from the company's second-quarter earnings call has been provided below. This transcript is brought to you by Benzinga